# I. Introduction ustained and controlled delivery of drugs to the ocular tissues continue to remain a major objective for formulation scientists and engineers in light of the emergence of more potent drugs and biological response modifications with limited biological half-lives. In ophthalmic drug delivery, in the front of the eye, the major hurdles of optimum drug bioavailability include rapid turnover, lacrimal drainage, reflex blinking and drug dilution by tears. Another physiological constraint is the limited permeability of cornea resulting into low absorption of ophthalmic drugs. A major portion of the administered dose drains into the nasolacrimal duct and thus can cause unwanted systemic side effects. Additionally, the rapid elimination of the drug through the punctum results in a short duration of the therapeutic effect resulting in a frequent dosing regimen. A significant challenge for the formulation is to circumvent these protective barriers of the eye without causing permanent damage to the tissue. Due to these physiological and anatomical barriers, only a very small fraction of the drug, usually 1-5% or even less of the instilled dose, is effectively absorbed. Frequent instillations of eye care solution are necessary to maintain a therapeutic drug level in the tear film or at the site of action. The frequent use of ophthalmic solutions may induce toxic side effects and cellular damage at the ocular surface. Moreover, once-a-day or twice-a-day formulations would like to improve patient compliance. # a) Materials Naphazoline hydrochloride, Pheniramine maleate, HPMC E4M, NaCMC, Benzalkonium chloride, Sodium chloride, NaoH. # II. Methods To prepare viscous eye care solution, different concentrations of HPMC E4M and NaCMC as per 3 2 factorial design were used. In order to obtain clear viscous solutions, accurately weighed HPMC E4M and NaCMC were dispersed and thoroughly hydrated in about 30 ml of the required amount of WFI. The dispersion was vigorously stirred and heated to 80-90°C, until the solution became clear. Then add weighed quantity of Sodium Chloride, Disodium Edetate, Disodium Hydrogen Phosphate, Sodium Hydroxide and at last add weighed quantity of drugs and Benzalkonium Chloride in about 40-50% of the required amount of WFI. Add this mixture to the dispersion of polymers while stirring. Adequate WFI was then added to obtain the required volume. The viscous solutions prepared with the excipients were sterilized at 121°C in autoclave for 20 min. Afterward, aqueous solutions were sterilized by filtration through 0.22 ?m sterile filter. The same formulation was prepared into simulated tear fluid in place of WFI. # III. Experimental Design Experimental designs are frequently used to establish an empirical relationship in terms of a mathematical model between dependent variables, and a number of factors or independent variables. To study all the possible combinations of all factors at all levels, a S Volume XV Issue II Version I Year 2 015 ( D D D D ) B two factor, three level full factorial design was constructed and conducted in a fully randomized order. The experimental design consists of total 9 experiments. The concentration of HPMC E4M (X 1 ) and concentration of NaCMC (X 2 ) was selected as formulation (independent) variables. The factor levels were chosen from the knowledge obtained from the preliminary studies. All other formulation and process variables were kept invariant throughout the study. Table 2 Summarizes the 9 experimental runs studied and their factor combinations and translation of the coded levels to the experimental units employed during the study. The viscosity (Y 1 ), Mucoadhesion index (Y 2 ), cumulative percentage drug released after 8 hrs. (Y 3 ) were studied as response variables (dependent variables).Design-Expert software (V.8.0.7.1, Stat-Ease Inc.) was used for the generation of the mathematical models. iv. Osmolarity The osmolarity of optimized sterilized viscous eye care solution was determined with a vapor pressure osmometer at room temperature. # v. Mucoadhesion Tes Mucin dispersion method was used to measure mucoadhesion index. Mucin Dispersion (MUC): MUC (15%w/v) was prepared by dispersing required amount of Mucin powder -into phosphate buffer (pH 7.4 ) and kept on magnetic stirrer at 600 rpm for 24 hrs for complete hydration and measured it viscosity (?m). To study the mucoadhesive interaction, 5 ml of polymer dispersion (?p) and 15 ml of MUC was mixed and determined its viscosity (?t) at 37°±1°C at shear rates D of 12.5, 25, 50, and 100 s -1 . An interaction between polymer and mucin should be seen as a synergistic effect in the rheological properties, which means that the rheological response of the Polymer/MUC mixture should be larger than the sum of the rheological responses of the single components polymer and mucin. Therefore, it is essential to rheologically characterise the single components as well as the polymer/MUC mixture. Trial No. Coded Factor X 1 Conc.of HPMC E4M (%w/v) X 2 Conc. Of NaCMC (%w/v) F1 1 1 F2 1 0 F3 1 -1 F4 0 1 F5 0 0 F6 0 -1 F7 -1 1 F8 -1 0 F9 -1 -1 vi. Sterilization Study Membrane filter of 0.2-?m porosity was used for sterilization by filtration in ?m aseptic area. The suitability of both methods of sterilization in the present study was tested by determining drug content of representative eye solution formulation of (aqueous based) before and after subjecting to sterilization by the respective method. Aqueous base solutions were prepared with 1 % drug and other excipients filled in vials and sealed. These vials were autoclaved for 20 minutes. In some other vials, solutions were filled by filtration through 0.2?m Millex, Millipore filter. # vii. Sterility testing The sterility testing of the viscous eye care solution was performed for the aerobic, anaerobic bacteria and fungi by using alternative thioglycolate medium (ATGM) and soyabean casein digest medium (SBCD). The positive control (growth promotion), negative control (sterlity) test was also conducted. Bacillus subtilis was used as a test organism in the case of aerobic bacteria test. Bacterio desvulgatus was used as a test organism in case of anaerobic bacteria test and candida albicans in fungi test. Incubation was carried in all cases and growth was checked. All the samples were inoculated separately in to ATGM and SBCD media and incubated at 35°C and 20-25°C, respectively for 7 days. Similarly unsterilized samples of films were also inoculated separately in to ATGM and SBCD media and incubated at 35°C and 20-25°C, respectively for 7 days. A control evaluation was also carried out. viii. Antimicrobial Test The test was performed according to USP. Cultures of bacteria [Escherichia coli (ATCC 4352), Pseudomonas aeruginosa (ATCC 9027), Staphylococcus aureus (ATCC 6538)] and fungi [Aspergillus niger (ATCC 16404) and Candida albicans (ATCC 10231)] were grown on solid agar media and soyabean casein digest media respectively. The test microorganism cultures were diluted with sterile WFI to obtain 10 -6 CFU/ml as per USP. All the cultures were transferred into 5 test tubes containing 10ml prepared eye drops(solution) and 0.1% prepared cultures in each. Initial counts were noted. These solutions were poured into petri plate containing Soya bean Casein Digest Agar Medium for bacterial cultures and Sabouraud Glucose Agar Medium for fungi. Keep them into incubator at 32.5±2.5ºC and 22.5±2.5ºC for bacteria and fungi respectively. Record the numbers of colony of microorganism at 7 th , 14 th and 28 th day. Check the criteria for preservative effectiveness for their acceptable range. ix. Invitro Diffusion study The Franz diffusion cell was used for studying the in vitro release of the viscous eye care solution(drops). A cellulose acetate membrane (Dialysis membrane with 25 mm diameter) was adapted to the terminal portion of the cylindrical donor compartment. 2.5 mL viscous eye drops containing drug, sufficient for establishing sink conditions for the assay was placed into the donor compartment. The receptor compartment contained 15 mL of Phosphate buffer solution of pH 7.4 maintained at 37°C under mild agitation using a magnetic stirrer. At specific time intervals, aliquots of 3mL will be withdrawn and immediately restored with the same volume of fresh phosphate buffer. The amount of drug released was assessed by measuring the absorbance at 261.6 nm and 272.4nm for Naphazoline and Pheniramine respectively using UV spectrophotometers. In order to analyze the drug release mechanism, in vitro release data was fitted into a zero-order, first order, Higuchi, And Korsmeyerpeppas model. x To assess the drug and formulation stability, stability studies was done according to ICH guidelines. Optimized formulation was kept in the stability chamber at specified temperature and humidity (40°±10°C and 75%RH) for one month. The chemical stability of the formulation was assessed by the estimation of the percentage drug remaining in the formulation and physical stability was evaluated by monitoring any change in pH, viscosity and appearance. Volume XV Issue II Version I # Result and Discussion Development of first order derivative spectroscopy method for simultaneous determination of NH and PM:-Selection of wavelength for simultaneous estimation of NH and PM :- Figure 1Figure 11 Figure 12 # a) pH The pH values for all formulations were shown in Table 4. The pH was within acceptable range (6.8 to 7.4) and would not cause any irritation upon administration of the formulation. # b) Refractive index Refractive index of tear fluid is 1.340 to 1.360. (Hussein et al.2009) It is recommended that eye care solution should have refractive index values not higher than 1.476. Table 4 depicts that Naphazoline hydrochloride and Pheniramine maleate viscous eye care solution had refractive index values ranging from 1.443 to 1.334 which are within the recommended values. Data reflected that no visual problem may cause in patient after administration of formulation. # c) Viscosity The longer contact time and effectiveness of the formulation in the eye is probably dependent not only on its mucoadhesive properties, but also on its viscosity and bulk rheological properties. Viscosity data of all the batches are shown in figures. Viscosity study in phosphate buffer 7.4 pH and in simulated tear fluid was carried out. From the rheograms shown in Fig. 14 & 15 medium remain same. From the data, it was found that batches F1, F4 and F7 shows very high viscosity due to highest concentration of NaCMC; was not selected as they were too viscous to instill properly into the eye. While, batches F6, F8 and F9 shows low viscosity due to lowest concentrations 0.5% HPMC, was not selected as aim of this study was to increase the viscosity of the formulations developed for residence time in ocular globe. Batches F3, F5 and F7 showed satisfactory viscosity. Each batch showed non-newtonian (dilatant) flow behaviour without any hysteresis. Non-newtonian solutions offer less resistance to movement of the eyelids over the globe and, therefore, are expected to be more comfortable in the eye than Newtonian solutions. By using the viscolysers like HPMC and NaCMC, viscosity of the prepared eye care solution was increased which gives longer contact time to the ocular globe. Therefore frequency of the instillation is decreased, which improves patient compliance. This increasing shear rate mimic ocular shear rates and respectively was found that viscosity in both the associated with normal blinking which is extremely wide, ranging from 0.03-28500S -1 . 7 and as per USP there should be 1 log reduction after 7 days, 3 log reductions after 14 days and no growth in population as compare to 14 th day after 28 days. In case of fungi, as per USP, there should be no growth/inhibition for AET. Optimized batch was obeyed the similar pattern of reduction in population as per standard limit and complies with the results. # Figure 14 Figure 15Figure 17 Figure 18 Figure 19 # f) Osmolarity The Osmolarity of the ophthalmic preparation should be in the range of 310-350 mOsmol/kg to avoid irritation. Osmolarity of optimized batches was found to be in the range and shows 325 mOsmol/kg which was within the acceptable tonicity range of the eye to avoid ocular irritation. V. # g) Animal Study # Conclusion Thus, on the basis of all the studies we can conclude that the batch having naphazoline hydrochloride and pheniramine maleate along with 0.59 % of HPMC E4M in the combination with 0.26 % NaCMC viscous solution may be considered as a promising for ophthalmic drug delivery.If the aforementioned formulation will scaled-up to manufacturing level, it will be used for potential sustained release effect for the allergic conjuctivitis. ![Journals Inc. (US) Year 2 015 Formulation & Evaluation of Eye Care Solution of Vasoconstrictor and Antihistaminic Drug for Conjuctivitis IV.](image-2.png "") 243![Figure 2](image-3.png "Figure 2 Figure 4 yFigure 3 y") 5![Figure 5 : FTIR spectra of physical mixture-II (Naphazoline Hydrochloride + Pheniramine Maleate + HPMC E4M + NaCMC)](image-4.png "Figure 5 :") 7![Figure 7 : DSC thermogram of physical mixture-III (Naphazoline Hydrochloride + Pheniramine Maleate + HPMC E4M + NaCMC)](image-5.png "Figure 7 :") 13![Figure 13 ](image-6.png "Figure 13") ![Journals Inc. (US)](image-7.png "") 5![Figure 16 ](image-8.png "5 )") 20![Figure 20 Contour plot (a) and response surface (b) plot showing the relationship between various level of polymer ( HPMC E4M & NaCMC) on viscosity](image-9.png "Figure 20") 10![Formulation & Evaluation of Eye Care Solution of Vasoconstrictor and Antihistaminic Drug for Conjuctivitis and Sterility testing Results of sterility test of optimized batches in both the media are shown in Table 5. It indicated absence of turbidity in media after 21 days of incubation period. This indicates absence of any contamination.](image-10.png "4 12 x 10 3") ![Figure 21](image-11.png "") 1Independent VariablesLevelsLowMediumHighX 1 = Concentration of HPMC E4M (% W/V)0.50.550.6X 2 = Concentration of NaCMC (% W/V)0.250.40.5Transformed values-101Y 1 = Viscosity(cps)Dependent variablesY 2 = Mucoadhesive IndexY 3 = Drug Release in 8 hr(%CDR) 2a) Evaluation Parametersi. ClarityClarity test was done by visual inspection ofeach container and by measuring the refractive indexusing refractometer at 25°c.ii. PHPH of prepared viscous eye care solution wasmeasured with pH meter.iii. ViscosityViscosity of batches F1-F9 by Brookfieldviscometer at different RPM. By plotting graph of RPMvs. viscosity, flow pattern was checked. 3Name of components 4BatchClaritypH (n= 3)Refractive IndexF1Slightly translucent7.40±0.021.469±0.001F2Clear7.40±0.011.431±0.001F3Clear7.41±0.011.356±0.001F4Slightly translucent7.40±0.011.465±0.002F5Clear7.40±0.031.358±0.002F6Clear7.40±0.011.341±0.001F7Slightly translucent7.41±0.011.471±0.001F8Clear7.41±0.021.341±0.002F9Clear7.40±0.011.334±0.001 5BatchMediaResultATGMSBCDF*ClearClearCompliesATGM-Alternative Thio glycolate media; SBCD -Soya bean casein digest mediae) Antimicrobial efficacy testing (AET)shown in TableThe microbial count for bacteria (Escherichia coli,Pseudomonas aeruginosa, Staphylococcus aureus) is 6CultureBatchInitial7 th day14 th day28 th dayCandida albicansF*15 x 10685 x 10546 x 10433 x 103Aspergillus NnigerF*9 x 10634 x 10552 x 10 7CultureBatchInitial7 th day14 th day28 th dayEscherichia ColiF*25 x 10518 x 104300253Pseudomonas aeruginosaF*19 x 10511 x 104287218Staphylococcus aureusF*22 x 10513 x 104240198 8FORMULATIONRABBIT ARABBIT BTIME (HR.)123456123456F*NNNNNN------CONTROLNNNNNN------OPCON A------NNNNNNCONTROL------NNNNNNS-Severe itching / irritation, M-Mild itching / irritation, N-No itching / irritation Stability 9DayspH*Assay of NH (% w/v)*Assay of PM (% w/v)*Assay of BKC (% w/v)*157.4 ± 0.0299.60±0.5499.34±0.3499.79±0.64307.41 ± 0.0199.41±0.8398.76±0.4399.58±0.90*Value Expressed as Mean ± SD (n=3) © 2015 Global Journals Inc. (US) Formulation & Evaluation of Eye Care Solution of Vasoconstrictor and Antihistaminic Drug for Conjuctivitis © 2015 Global Journals Inc. (US) Year 2 015 * Current therapy of allergic conjunctivitis MBisca Current Therapeutic Research 58 1997 * Industrial perspective in ocular drug delivery AliYa KLehmussaari Advanced Drug Delivery Reviews 58 2006 * An overview and advancement in ocular drug delivery systems Rathore International Journal of Pharmaceutical Science & Research 46 2010 * Current and future ophthalmic drug delivery systems, A Shift to the posterior segment MEva AtourttiDel Amo Drug Discovery Today 13 2008 * Ocular pharmacokinetics MauriceDm SPMishima Handbook Of Experimental Pharmacology 1984 Berlin-Heidelberg Publication 15th Edition * Recent perspectives in ocular drug delivery-expert review RipalGaudana AndSaih A Pharmaceutical Research 26 2009 * Dexamethasone eye drops containing alpha cyclodextrin-based nanogels MariaDMoya-Ortega International Journal of Pharmaceutics 44 2013 * Microemulsion as potential drug delivery system AnsariMj Kohli Pdaj. Pharma Science Techno 62 2008 * Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs MAKassem AAAbdelrahman Int. J. Pharm 340 2007 * Liposomes as an ocular delivery system for acetazolamide: in-vitro and in vivo studies RMHathout SMansour Aaps Pharm scitech 8 1 2007 * Poly (amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide TFVandammeand LBrobeck J. Control Release 4 2007 * Vesicular systems in ocular drug delivery KaurIp Int. J. Pharm 2 2010 * Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles JLBourges SEGautier Invest * Ophthalmol. Vis. Sci 44 2003 * Intraocular implants for extended drug delivery: therapeutic applications JLBourges FBehar-Cohen Adv. Drug Delivery Review 58 2006 * Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye SigurdssonHh EStefansson Acta. Ophthalmol. Scand 85 2007 * Ophthalmic drug delivery through contact lenses DGulsenand AChauhan Invest Ophthalmol Vis Science 45 2004 * A novel approach sustained ocular drug delivery: In-situ Gel HiteshSharma International Journal of Research in Pharmacy and Life Science 1 2 2013 * Current ocular drug delivery challenges for N-acetyloxcarnosine: novel patented routes and modes of delivery, design for enhancement of therapeutic activity and drug delivery relationships AMark Babizhayev Drug Delivery & Formulation 18 2009 Recent Patents on * Tolerance of ocular iontophoresis in healthy volunteers TMParkinson MMundasad J. Ocul. Pharmacol. Therapy 19 2003 * Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy KJoossand NChirmule Gene Therapy 10 2003 * An insight into ophthalmic drug delivery system KSRathore RKNima International Journal of Pharmaceutical Science and Drug Research 47 2009 * The Handbook of Ocular Disease Management * Allergic conjunctivitis: update on pathophysiology and prospects for future treatment SantaJMark BA * United State Pharmacopeia and National Formulary (USP 30) 2707 Naphazoline Hydrochloride Monograph * United State Pharmacopeia and National Formulary (USP 30) Pheniramine Maleate Monograph * The use of mucoadhesive polymers in ocular drug delivery Annickludwig Advanced Drug Delivery Reviews 7 2005 * Influence of the physico-chemical properties of ophthalmic viscolysers on the weight of drops dispensed from a flexible dropper bottle VanSantvliet AKLudwig European Journal of Pharmaceutical Sciences 95 1999 * Mucoadhesive nanopolymer -a novel drug carrier for topical ocular drug delivery Soumendra Sahoo Al European Journal of Scientific Research 46 2010 * Handbook of Pharmaceutical Excipients CRaymond Rowa CSiân Owen 2006 The Pharmaceutical Press 6 th edn * Tamarind seed polysaccharide: a versatile biopolymer for mucoadhesive applications SahooSoumendra Journal of Pharmaceutical and Biomedical Sciences 8 20 2010 * Handbook of Pharmaceutical Excipients CRaymond Rowa CSiân Owen 2006 The Pharmaceutical Press 6 th edn * Handbook of Pharmaceutical Excipients CRaymond Rowa CSiân Owen 2006 The Pharmaceutical Press 6 th edn * A comparative rheological study on carbopol viscous solutions and evaluation of their suitability as the ophthalmic vehicle and artificial tears NUnlu ALudwig Pharma Act 67 1 1992 * A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery ViannaLopez European Journal of Pharmaceutics and Biopharmaceutics 75 2010 * Synergistic interaction between TS-polysaccharide and hyaluronic acid: implications in the formulations of eye drops GUBarretta SNazzi International Journal of Pharmaceutics 395 2011 * Formulation and Invitro evaluation of cysteamine hydrochloride viscous solution for treatment of corneal cystinosis KoraygumSibelbozdag European Journal of Pharmaceutics and Biopharmaceutics 70 2008 * Pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model VGJack Clinical Therapeutics 27 2005 * In-situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride DAttwood International Journal of Pharmaceutics 229 2001 * Formulation and evaluation of ophthalmic preparations of acetazolamide IPKaur International Journal of Pharmaceutics 199 2000 * Topical use of chitosan in ophthalmology: tolerance assessment and evaluation of precorneal retention OFelt International Journal of Pharmaceutics 180 1999 * Eye preparation for treating medicine, US Patents 03132242 FormingJingcai 2004 * Method and composition for treatment of skin conditions, US Patents PCT JeffreyHutterer US2005/010269,2005 * Ophthalmic compositions including glycerin and propylene glycol, US Patents US 08/794 JohnDenick ZhenzeHu 1998 690 * Ketorolac tromethamine compositions for treating ocular pain Farnes US Patents 12/396 2009 131 * Ophthalmic formulation, US Patents US 081329 OrestOlejnik FredWWendel 1997 808 * Improved ocular: systemic absorption ratio of timolol by viscous vehicle and phenylephrine KrisriinoKyyronen Arrourrri Investigative Ophthalmology & Visual Science 15 1990 * Formulation and Invitro evaluation of cysteamine hydrochloride viscous solution for treatment of corneal cystinosis KoraygumSibelbozdag European Journal of Pharmaceutics and Biopharmaceutics 70 2008 * Development and evaluation of pH triggered in-situ ophthalmic gel formulation of ofloxacin PBPatel DHShastri American Journal of Pharmtech Research 1 2011 * Effect of a single drop of latanoprost ophthalmic gel on intra ocular pressure in the treatment of glaucoma SVKulkarni HNSandeep International Journal of Pharmaceutical Sciences 2 2010 * Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride OAHussein HASalama AAPS Pharmscitech 10 2009 * Formulation and Invitro evaluation of cysteamine hydrochloride viscous solution for treatment of corneal cystinosis KoraygumuSibelbozdag European Journal of Pharmaceutics and Biopharmaceutics 70 2008 * Polyacrylic acid/ polyvinylpyrrolidone bipolymeric systems.i. Rheological and mucoadhesive properties of formulations potentially useful for the treatment of dry-eye-syndrome MatthiasOSigrid K European Journal of Pharmaceutics and Biopharmaceutics 47 1999 * Cyclodextrin solubilization of carbonic anhydrase inhibitor drugs: formulation of dorzolamide eye drop microparticle suspension PJansook EStefánsson European Journal of Pharmaceutics and Biopharmaceutics 76 2010 * Solubility enhancement of water insoluble drug for ophthalmic formulation SunishaKulkarni Int. J. of Drug Delivery 3 2011 * Ophthalmic drug delivery systems recent advances CLBourlais LAcar Progress In Retinal And Eye Research 17 1998 * Topical semi-solid drug delivery: kinetics and tolerance of ophthalmic hydrogels MZignani CTabatabay Adv Drug Deliv Rev 16 1995 * Selected polysaccharide at comparison for their mucoadhesiveness and effect on precorneal resident of different drugs in rabbit model GDColo YZambito Drug. Dev. and Ind. Pharmacy 35 2009 * A novel poloxamers/ hyaluronic acid in situ forming hydrogel for drug delivery: rheological, mucoadhesive and in vitro release properties LMayol FQuaglia European Journal of Pharm and Biopharms 70 2008 * Stimuli-sensitive hydrogels in controlled and sustained drug delivery RMasteikova ZChalupova Medicina 39 2003 * A study on stability and in-vivo drug release of naphazoline and antazoline in situ gelling systems for ocular delivery GNShetty RNCharyulu Int J of Pharm Bio Sci 4 1 2013 * In-vivo evaluation of dexamethasone sodium phosphate nanoparticles for post cataract treatment VSankara Pharmacologyonline 8 2009